Loading...
XNAS
BVS
Market cap474mUSD
Dec 05, Last price  
7.09USD
1D
-6.96%
1Q
-1.39%
IPO
-58.83%
Name

Bioventus Inc

Chart & Performance

D1W1MN
XNAS:BVS chart
P/E
P/S
0.83
EPS
Div Yield, %
Shrs. gr., 5y
2.84%
Rev. gr., 5y
11.00%
Revenues
573m
+11.89%
64,774,000232,375,000242,893,000253,650,000274,500,000292,059,000319,177,000340,141,000321,161,000430,898,000512,117,000512,345,000573,280,000
Net income
-34m
L-78.53%
-39,222,000-22,367,000-12,900,000-34,111,000-17,953,000-1,639,000-12,207,0006,851,00016,411,0009,586,000-213,391,000-156,230,000-33,542,000
CFO
39m
+152.83%
2,749,00015,109,00018,920,00045,187,00040,713,00071,799,00022,991,000-13,537,00015,344,00038,795,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
IPO date
Feb 11, 2021
Employees
950
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT